SPLINT may leads to higher overall improvement (improved/not improved or worsened) ‐ short‐term… compared with NO ACTIVE TREATMENT (low certainty).
SPLINT showed no clear difference in adverse effects compared with NO ACTIVE TREATMENT (low certainty).
It is very uncertain whether SPLINT changes referral for surgery compared with NO ACTIVE TREATMENT (very low certainty).
It is very uncertain whether vitamin D (all doses) changes clinical response at end of study (4 weeks) compared with placebo/no treatment (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
Vitamin D (all doses) may leads to lower clinical relapse at end of study (26–52) weeks compared with placebo/no treatment (low certainty).
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
The review found no eligible studies for this question.
High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
The review found no eligible studies for this question.
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
Infliximab 5 mg/kg may leads to higher clinical remission at week 26 compared with purine analogues (low certainty).
Infliximab 5 mg/kg may leads to higher clinical response at week 26 compared with purine analogues (low certainty).
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).